PMID- 15172443
OWN - NLM
STAT- MEDLINE
DCOM- 20050321
LR  - 20231213
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 65
IP  - 5
DP  - 2004 May
TI  - HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T 
      lymphocytes.
PG  - 437-45
AB  - Natural killer (NK)-cytotoxic T lymphocytes (CTL) are a subset of CD8(+) 
      cytolytic T lymphocytes that express human leukocyte antigen (HLA) class 
      I-specific inhibitory receptors. They are detectable as monoclonal expansions in 
      the blood of cytomegalovirus (CMV)-seropositive individuals displaying particular 
      HLA-Cw allotypes. Similar to NK cells, they are capable of killing various 
      allogeneic tumor cell lines, a function referred to as "NK-like activity." The 
      mechanism underlying this unusual functional property has recently been 
      clarified. Via their T-cell receptor, NK-CTL recognize the nonclassical HLA class 
      I molecule HLA-E, which is characterized by a limited polymorphism and by the 
      ability to bind peptides derived from the leader sequence of various HLA class I 
      alleles as well as from few viral proteins. The analysis of the T-cell receptor 
      avidity revealed that NK-CTL recognize with high avidity a CMV UL40-derived 
      peptide. The HLA-E-restricted recognition of CMV by NK-CTL may represent an 
      important immunologic strategy in defenses against this virus. Indeed, unlike 
      conventional CTL, NK-CTL mediated lysis is apparently not affected by the 
      downregulation of major histocompatibility complex class I that occurs during CMV 
      infection. Because the CMV UL40-derived peptide is identical to the one generated 
      from the leader sequence of various HLA-Cw alleles, NK-CTL are also able to 
      display an "HLA-E-dependent alloreactivity" against allogeneic target cells 
      expressing appropriate HLA-Cw alleles. This broad ability to recognize and kill 
      allogeneic cells may pose serious problems in transplantation.
FAU - Romagnani, Chiara
AU  - Romagnani C
AD  - Dipartimento di Medicinia Sperimentale, Centro di Eccellenza per Ricerche 
      Biomediche , Universita degli Studi di Genova, Genova, Italy.
FAU - Pietra, Gabriella
AU  - Pietra G
FAU - Falco, Michela
AU  - Falco M
FAU - Mazzarino, Paola
AU  - Mazzarino P
FAU - Moretta, Lorenzo
AU  - Moretta L
FAU - Mingari, Maria Cristina
AU  - Mingari MC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 3)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Tap2 protein, mouse)
RN  - 0 (UL40 glycoprotein, Cytomegalovirus)
RN  - 0 (Viral Proteins)
RN  - 0 (beta 2-Microglobulin)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 3
MH  - ATP-Binding Cassette Transporters/genetics
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/pharmacology
MH  - Cell Line
MH  - Cytomegalovirus/*immunology
MH  - Cytotoxicity Tests, Immunologic
MH  - Cytotoxicity, Immunologic/drug effects/immunology
MH  - Flow Cytometry
MH  - HLA Antigens/genetics/*immunology
MH  - HLA-C Antigens/immunology
MH  - Herpesvirus 4, Human/immunology
MH  - Histocompatibility Antigens Class I/genetics/*immunology/metabolism
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Killer Cells, Natural/immunology
MH  - Mice
MH  - Peptide Fragments/immunology/metabolism
MH  - Receptors, Antigen, T-Cell/immunology
MH  - T-Lymphocyte Subsets/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Transfection
MH  - Viral Proteins/genetics/immunology
MH  - beta 2-Microglobulin/genetics/immunology
MH  - HLA-E Antigens
EDAT- 2004/06/03 05:00
MHDA- 2005/03/22 09:00
CRDT- 2004/06/03 05:00
PHST- 2003/08/12 00:00 [received]
PHST- 2004/01/15 00:00 [revised]
PHST- 2004/02/03 00:00 [accepted]
PHST- 2004/06/03 05:00 [pubmed]
PHST- 2005/03/22 09:00 [medline]
PHST- 2004/06/03 05:00 [entrez]
AID - S0198885904000370 [pii]
AID - 10.1016/j.humimm.2004.02.001 [doi]
PST - ppublish
SO  - Hum Immunol. 2004 May;65(5):437-45. doi: 10.1016/j.humimm.2004.02.001.